Exploring the potential of a new class of drug candidates with Vicore Pharma's CEO, focusing on angiotensin II type 2 receptor agonists for treating rare respiratory diseases. Discussions on technology, collaboration, challenges in addressing idiopathic pulmonary fibrosis, and opportunities in drug development in Sweden.

This podcast highlights the discovery of antibodies targeting a new influenza target, a novel bi-specific antibody for inflammatory disorders, advancements in severe asthma management, and the safety and efficacy of D'Ananamab for Alzheimer's disease.

Exploring 3D chemistry and AI for small molecule therapies, single-cell gene expression in next-gen sequencing, and CDMOs supporting mRNA developers. Advantages of AI in drug design, SC RNA sequencing for cancer research, and advancements in mRNA therapeutics manufacturing.

FDA approves first cell therapy for solid tumors; Breakthrough in islet cell therapy for diabetes; FDA approval of AMTAGVY for melanoma; Advances in cell and gene therapy manufacturing; Collaboration in immuno-oncology therapeutics; Tau-targeting therapies for Alzheimer's disease

In this podcast, Quin Wills from Ochre Bio discusses using AI to unlock the potential of complex human liver data. They are building components of the liver from scratch to study metabolic, cell death, inflammation, fibrosis, and neoplastic processes. The aim is to conduct 'clinical trials' before actual clinical trials, with a focus on enhancing success rates with modalities like SIRNA and addressing urgent global liver disease concerns.

This podcast episode highlights innovative treatments for systemic sclerosis using AM1476, discusses diverse pipeline options for skin conditions, and shares insights on Hidradenitis Suppurativa and Bermikizumab treatment.

For this year’s SLAS2024 conference in Boston (which takes place 3-7 February), DDW’s Megan Thomas narrates articles from the DDW SLAS2024 supplement as part of the DDW Events podcast series. This is episode five, Solving the diagnostic odyssey with multi-omics. Catherine Brownstein is an Assistant Professor in Pediatrics at Harvard Medical School and the Assistant Director of the Molecular Genetics Core Facility at Boston Children's Hospital. Her current work focuses on advancing the fields of genome sequencing and analysis, with an emphasis on identifying complex structural variation. She spoke with me on how genomics can advance drug discovery and development.

For this year’s SLAS2024 conference in Boston (which takes place 3-7 February), DDW’s Megan Thomas narrates articles from the DDW SLAS2024 supplement as part of the DDW Events podcast series. This is episode four, The building blocks of AI success stories. Dr Mike Tarselli, Chief Scientific & Knowledge Officer at TetraScience, was Scientific Director of SLAS until 2020, and will be chairing his first event this year. He shares his insight with me in this episode.

For this year’s SLAS2024 conference in Boston (which takes place 3-7 February), DDW’s Megan Thomas narrates articles from the DDW SLAS2024 supplement as part of the DDW Events podcast series. This is episode three, Connecting academia, industry and the public. Erin Welsh, PhD, is a disease ecologist and epidemiologist now working full-time as a science communicator. Erin Allmann Updyke, MD, PhD is an epidemiologist and disease ecologist currently in a medical residency programme to complete her training. Together, they make up This Podcast Will Kill You. Ahead of being a keynote speaker at SLAS 2024, Welsh shares insight with DDW.

For this year’s SLAS2024 conference in Boston (which takes place 3-7 February), DDW’s Megan Thomas narrates articles from the DDW SLAS2024 supplement as part of the DDW Events podcast series. This is episode two, Where is the Ignite Theater tech leading us? At this year's SLAS event, DDW has curated a track taking place in the Ignite Theater, sponsored by Integra Biosciences and Hamamatsu Corporation. It will explore technologies being used for drug discovery and how they get from lab to patient.